Immune checkpoint inhibitors (ICIs), represented by programmed death-1 (PD-1)/ programmed death ligand-1 (PD-L1) inhibitors, have significantly improved efficacy in patients with advanced NSCLC, but the efficacy in patients with NSCLC and liver metastases remains controversial. Here, CD274 is linked to non-small cell lung carcinoma.